Stealth BioTherapeutics: Preclinical Data Shows Neuroprotective Effect Of SBT-272

(RTTNews) - Stealth BioTherapeutics Corp. (MITO) presented promising data from a study evaluating the effects of SBT-272 in a murine model of Parkinson's disease. The data showed that SBT-272 has a neuroprotective effect in this model of Parkinson's disease. This was supported by an additional collaborative study between Stealth BioTherapeutics and investigators from the Latvian Institute for Organic Synthesis, in which systemic SBT-272 treatment protected brain mitochondria against damage caused by ischemic stroke.

The company said, taken together, these data highlight the potential of SBT-272 as a systemically administered therapy for treating neurodegenerative diseases.

The company plans to advance SBT-272 in dose-ranging phase 1 clinical studies early next year in addition to initiating chronic toxicology studies to support Phase 2 initiation.

Shares of Stealth BioTherapeutics were up 3% in pre-market trade on Thursday.